Table 2

Prevalence of autoantibodies in 863 scleroderma patients

Autoantibodies

Patients, n (%)


Positive for antinuclear antibodies

813 (94.2)

Antibodies highly associated with SSc or scleroderma overlap syndromes

704 (81.6)

Anti-centromere

310 (35.9)

Anti-topoisomerase I

260 (30.1)

Anti-PM-Scl

42 (4.9)

Anti-U1-RNP

41 (4.8)

Anti-RNA polymerase

33 (3.8)

Anti-fibrillarin

12 (1.4)

Anti-To

2 (0.2)

Anti-Ku

10 (1.2)

Anti-Jo-1/-Pl-7/-OJ

4 (0.5)

Anti-U11-RNP

1 (0.1)

Other autoantibodies

Anti-Ro and/or anti-La

206 (23.9)

Anti-Ro52

187 (21.7)

Anti-Ro60

59 (6.8)

Anti-La

16 (1.9)

Anti-mitochondrial M2

41 (4.8)

Anti-p25/p23

28 (3.2)

Anti-NOR-90

6 (0.7)

Anti-SL

9 (1.0)

Anti-Sm

4 (0.5)

Anti-Sp100

4 (0.5)

Other (known or unknown)

363 (42.1)

Negative for all highly SSc-associated antibodies

159 (18.4)

Negative for antinuclear antibodies

50 (5.8)

Autoantibody-negative by all criteria used

38 (4.4)


ANA = antinuclear antibodies; SSc = systemic sclerosis.

Mierau et al. Arthritis Research & Therapy 2011 13:R172   doi:10.1186/ar3495

Open Data